Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
TNFRSF1A	7132	CYCLOPHOSPHAMIDE	CHEMBL88		NCI	9894568

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
TNFRSF1A	rs767455	TT	adalimumab	efficacy	no	No significance association between genotype and response to the anti-TNFalpha drugs after 6 months of treatment was seen. Response to therapy was assessed according to EULAR response criteria. Please note alleles have been complemented to the plus chromosomal strand.	Genotype TT is not associated with response to adalimumab, etanercept and infliximab in people with Arthritis, Psoriatic as compared to genotypes CC + CT.	22480748	982046956
TNFRSF1A	rs767455	TT	Tumor necrosis factor alpha	efficacy	yes	Significantly more patients with the homozygous TT genotype achieved a good response according to EULAR criteria (European League Against Rheumatism) after 3 months of treatment compared to patients who carried the C allele (p=0.011). Additionally, after 6 months of treatment, remission of disease or low disease activity was more frequently observed in patients with the TT genotype as compared to those with the CC genotype (p=0.04). Please note that alleles have been complemented to the plus chromosomal strand.	Genotype TT is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotype CC.	25311255	1445585200
TNFRSF1A	rs2234649	GT	etanercept	efficacy	no	Response to etanercept was determined using the Assessment in Ankylosing Spondylitis 20 (ASAS20) and Assessment in Ankylosing Spondylitis 40 (ASAS40). No significant difference in response was seen between genotypes at either 3 months or 12 months after initiation of etanercept treatment. Please note that alleles have been complemented to the positive strand. Also note that there appears to be a typo in Figure 1 where rs2234649 is written as rs223464.	Genotype GT is not associated with response to etanercept in people with Spondylitis, Ankylosing as compared to genotypes GG + TT.	30075559	1449713726
TNFRSF1A	rs767455	TT	adalimumab	efficacy	yes	Patients with the TT genotype had poorer response to the anti-TNFalpha drugs after 3 months of treatment. Response to therapy was assessed according to EULAR response criteria. Please note alleles have been complemented to the plus chromosomal strand.	Genotype TT is associated with decreased response to adalimumab, etanercept and infliximab in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.	22480748	982046877
TNFRSF1A	rs767455	TT	adalimumab	efficacy	no	No significance association between genotype and response to the anti-TNFalpha drugs after 6 months of treatment was seen. Response to therapy was assessed according to EULAR response criteria. Please note alleles have been complemented to the plus chromosomal strand.	Genotype TT is not associated with response to adalimumab, etanercept and infliximab in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.	22480748	982046951
TNFRSF1A	rs767455	TT	adalimumab	efficacy	yes	The TT genotype was associated with a better response after 3 months of treatment with anti-TNFalpha drugs. Response to therapy was assessed according to EULAR response criteria. Please note alleles have been complemented to the plus chromosomal strand.	Genotype TT is associated with increased response to adalimumab, etanercept and infliximab in people with Arthritis, Psoriatic as compared to genotypes CC + CT.	22480748	982046897
TNFRSF1A	rs767455	CT	etanercept	efficacy	no	Response to etanercept was determined using the Assessment in Ankylosing Spondylitis 20 (ASAS20) and Assessment in Ankylosing Spondylitis 40 (ASAS40). No significant difference in response was seen between genotypes at either 3 months or 12 months after initiation of etanercept treatment.	Genotype CT is not associated with response to etanercept in people with Spondylitis, Ankylosing as compared to genotypes CC + TT.	30075559	1449713713
TNFRSF1A	rs4149570	AA	Tumor necrosis factor alpha	efficacy	yes	Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for IBD and CD cohorts. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation. Please note alleles have been complemented to the plus chromosomal strand.	Genotype AA is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease or Inflammatory Bowel Diseases as compared to genotypes AC + CC.	24776844	1296666759